TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Evozyne Stock

Evozyne Stock

www.evozyne.com/Enterprise Software / Other Enterprise SoftwareFounded: 2020Funding to Date: $109.19MM

Evozyne, founded in 2019, is an artificial intelligence and biotechnology company that uses generative AI models with the goal of creating advanced therapeutic proteins and pharmaceuticals. The company’s platform was built on an AI model called ProT-VAE that was trained by AI hardware company Nvidia, and it is designed to read sequences on amino acids with the goal of enabling it to understand how nature assembles proteins. Evozyne is headquartered in Chicago, Illinois.

Buy or sell Evozyne stockLearn more about Evozyne IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Evozyne, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Evozyne’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Evozyne.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Evozyne investors also invested in these private companies

Valor Equity Partners
Fidelity Management and Research Company
NVIDIA
OrbiMed
NVentures
Paragon Biosciences

Team

Management Team

Patrick Morris
Executive Vice President of Legal Affairs, Manager, President & General Counsel
Mike Gamson
Chief Executive Officer
Rama Ranganathan Ph.D
Co-Founder, Chief Scientific Officer & Manager
Uri Herzberg Ph.D
Chief Drug Discovery Officer
Aris Theologis
Chief Business Officer
Andrew Ferguson Ph.D
Co-Founder, Head of Computation & Computational Advisor
Zach Serber Ph.D
Chief Operating Officer

Frequently Asked Questions About Evozyne’s Stock

plusminus
Can you buy Evozyne’s stock?
Evozyne is not publicly traded on NYSE or NASDAQ in the U.S. To buy Evozyne’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Evozyne’s stock?
Yes, you can sell stock of a private company like Evozyne. Forge can help you sell your Evozyne stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Evozyne’s stock price?
Evozyne is a privately held company and therefore does not have a public stock price. However, you may access Evozyne’s private market stock price with Forge Data.
plusminus
What is Evozyne’s stock ticker symbol?
Evozyne does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Evozyne in the Other Enterprise Software sector

Bubble

Sector
Enterprise Software / Other Enterprise Software
Last Round Est. Valuation
$489.38MM

Kaseya

Sector
Enterprise Software / Other Enterprise Software
Last Round Est. Valuation
$1.75B

ContentSquare

Sector
Enterprise Software / Other Enterprise Software
Last Round Est. Valuation
$315.92MM

RELEX Solutions

Sector
Enterprise Software / Other Enterprise Software
Last Round Est. Valuation
$450MM

Digital Asset

Sector
Enterprise Software / Other Enterprise Software
 
 

Guru

Sector
Enterprise Software / Other Enterprise Software
Last Round Est. Valuation
$174MM

Genesys

Sector
Enterprise Software / Other Enterprise Software
Last Round Est. Valuation
$21B

Framer

Sector
Enterprise Software / Other Enterprise Software
 
 

Decisiv

Sector
Enterprise Software / Other Enterprise Software
Last Round Est. Valuation
$125MM

News Highlights

Business Wire 09/27/2023
Evozyne Announces $81 Million Financing Round to Advance Generative AI for Therapeutic Discovery and Drug Development
Evozyne announced the closing of an $81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development. Fidelity Management & Research Company and OrbiMed led the funding with participation from NVentures, NVIDIA’s venture capital arm.

Trending Companies

Frequently Asked Questions

Updated on: Apr 27, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.